After surging 6.87 per cent to Rs 1,022 in intra-day trade at the BSE, shares of the company finally ended at Rs 1,009.80, up 5.59 per cent.
At the NSE, the company's scrip settled with a gain of 5.78 per cent at Rs 1,011.90.
Tracking the gain in the stock, the company's market valuation went up by Rs 1,510.13 crore to Rs 28,492.13 crore.
Glenmark Pharmaceuticals yesterday posted 3.29 per cent rise in consolidated net profit at Rs 190.93 crore for the first quarter ended June 30, driven by sales in domestic as well as overseas markets.
The company's consolidated revenue, excluding outlicensing income, stood at Rs 1,655.24 crore for the first quarter, as compared to Rs 1,457.03 crore in the same period of the previous fiscal, the firm had said in a filing to the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
